Similar Search Results

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?

Knoll, Stefanie; Mair, Christoph; Benter, Ursula; Vouk, … - In: Health Economics Review 3 (2013) 27, pp. 1-11

cost-saving intervention from the perspective of the statutory health insurance (SHI) in Germany. Objective: The objective … to the SHI when comparing 100% rotavirus vaccination with no vaccination in Germany. Methods: A Markov cohort model …-based physicians due to the vaccine's efficacy against severe disease. Conclusions: Routine rotavirus vaccination in Germany would …

Persistent link: https://www.econbiz.de/10011599774

Forgone care and financial burden due to out-of-pocket payments within the German health care system

Bremer, Patrick - In: Health Economics Review 4 (2014) 36, pp. 1-9

Background: The amount of out-of-pocket (OOP) payments within the German health care system has risen steadily within the last years. OOP payments aim to strengthen patients' cost awareness and try to restrict the demand on medical necessary treatments. However, besides the intended decline of...

Persistent link: https://www.econbiz.de/10011599778

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany

Neubauer, Sarah; Cifaldi, Mary; Mittendorf, Thomas; … - In: Health Economics Review 4 (2014) 32, pp. 1-11

inhibitors adalimumab, etanercept, and infliximab in rheumatoid arthritis (RA) patients treated in Germany. Methods: In this …

Persistent link: https://www.econbiz.de/10011599782

Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany

Schwander, Bjoern - In: Health Economics Review 4 (2014) 27, pp. 1-10

Germany. The innovative nature, the high unmet medical need and the expected unprecedented efficacy of next generation AVDs …

Persistent link: https://www.econbiz.de/10011599786

Preferences for health insurance in Germany and the Netherlands: A tale of two countries

Leukert-Becker, Karolin; Zweifel, Peter - In: Health Economics Review 4 (2014) 22, pp. 1-11

Background: This contribution seeks to measure preferences for health insurance in Germany and the Netherlands, using …

Persistent link: https://www.econbiz.de/10011599791

Parents' willingness to pay for the prevention of childhood overweight and obesity

Kesztyüs, Dorothea; Lauer, Romy; Schreiber, Anja C.; … - In: Health Economics Review 4 (2014) 20, pp. 1-8

Objective: To determine parental willingness-to-pay (WTP) for childhood obesity prevention. Methods: Cross-sectional data from the follow-up measurements (2011) of a health promotion programme in German primary schools. Data collection included anthropometric measurements of children and...

Persistent link: https://www.econbiz.de/10011599793

Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework

Kotsopoulos, Nikolaos; Connolly, Mark P.; Remy, Vanessa - In: Health Economics Review 5 (2015) 23, pp. 1-11

a lifetime cost-benefit analysis of investing in universal vaccination in Germany from the perspective of government … the cohorts. After taking into consideration the governmental transfers, universal HPV vaccination in Germany could result …

Persistent link: https://www.econbiz.de/10011599848

Costs and treatment patterns of incident ADHD patients: A comparative analysis before and after the initial diagnosis

Klora, Mike; Zeidler, Jan; Linder, Roland; Verheyen, Frank - In: Health Economics Review 5 (2015) 40, pp. 1-9

subjects of health services research in Germany and worldwide. Previous publications focused mainly on prevalent patients and …

Persistent link: https://www.econbiz.de/10011599865

Defining Hospital Markets - An Application to the German Hospital Sector

Hentschker, Corinna; Mennicken, Roman; Schmid, Andreas - In: Health Economics Review 4 (2014) 28, pp. 1-17

The correct definition of the product market and of the geographic market is a prerequisite for assessing market structures in antitrust cases. For hospital markets, both dimensions are controversially discussed in the literature. Using data for the German hospital market we aim at elaborating...

Persistent link: https://www.econbiz.de/10011402867

Hepatocellular carcinoma after prior sorafenib treatment: Incidence, healthcare utilisation and costs from German statutory health insurance claims data

Clouth, Johannes; Liepa, Astra M.; Moeser, Guido; … - In: Health Economics Review 8 (2018) 18, pp. 1-10

-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods …-sorafenib. Results: Between 1032 and 1484 patients with HCC in Germany (893-1390 publicly insured patients) were estimated as likely to … publicly insured HCC patients annually eligible for second-line therapy in Germany was < 1400 and mean total costs accrued in …

Persistent link: https://www.econbiz.de/10012010774